

## **DURECT to Present at the Cantor Fitzgerald Healthcare Conference**

CUPERTINO, Calif., June 28, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Tuesday, July 12 at 8:00 a.m. Eastern Time. The conference is being held at Le Parker Meridien Hotel in New York City. Investors and analysts that are attending the conference may request a one-on-one meeting through the conference organizers at <a href="http://www.meetmax.com/sched/event-37633/investor-reg-new.html?attendee-role-id=INVESTOR">http://www.meetmax.com/sched/event-37633/investor-reg-new.html?attendee-role-id=INVESTOR</a>

A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/cantor4/drrx.

A live audio webcast of the presentation will also be available by accessing DURECT's homepage at <a href="www.www.durect.com">www.www.durect.com</a> and clicking "Investor Relations."

If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

## **About DURECT Corporation**

DURECT is a biopharmaceutical company focused on two areas of active drug development: new therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its Epigenomic Regulator Program. Its drug development expertise is being applied primarily to the fields of pain management, CNS disorders, acute organ injury and metabolic diseases such as NAFLD/NASH. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. Late stage development programs of this nature include POSIMIR® (SABER®-Bupivacaine) and REMOXY® (ORADUR®-oxycodone). DURECT's Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival. For more information, please visit www.www.durect.com.

NOTE: POSIMIR®, SABER® and ORADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. POSIDUR, REMOXY and DUR-928 are investigational drugs under development and have not been approved for sale by the U.S. Food and Drug Administration or other health authorities.

To view the original version on PR Newswire, visit<a href="http://www.prnewswire.com/news-releases/durect-to-present-at-the-cantor-fitzgerald-healthcare-conference-300291453.html">http://www.prnewswire.com/news-releases/durect-to-present-at-the-cantor-fitzgerald-healthcare-conference-300291453.html</a>

SOURCE DURECT Corporation

Matthew J. Hogan, Chief Financial Officer, DURECT, 408-777-4936